Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 10/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21190345 | 1.00 | CKS1B (0.46) | CKS1BSKP1SKP2SUV39H2CNR1 | |
| SCHEMBL28957009 | 0.87 | RET (0.42) | CKS1BSKP1SKP2CYP8B1 | |
| SCHEMBL29604165 | 0.87 | JAK1 (0.39) | CKS1BSKP1SKP2SUV39H2DRD2 | |
| SCHEMBL28867788 | 0.87 | CYP8B1 (0.42) | CKS1BSKP1SKP2SUV39H2CNR1 | |
| SCHEMBL21173531 | 0.86 | CKS1B (0.54) | CKS1BSKP1SKP2SUV39H2CNR1 | |
| SCHEMBL21143330 | 0.85 | CYP8B1 (0.41) | CYP8B1ATMSMO | |
| SCHEMBL29798625 | 0.85 | CKS1B (0.46) | CKS1BSKP1SKP2SUV39H2CNR1 | |
| SCHEMBL30897161 | 0.85 | SSTR2 (0.48) | CKS1BSKP1SKP2 | |
| SCHEMBL21819981 | 0.84 | CYP8B1 (0.42) | CKS1BSKP1SKP2SUV39H2CYP8B1 | |
| SCHEMBL28867854 | 0.84 | CYP8B1 (0.42) | CKS1BSKP1SKP2SUV39H2CYP8B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267295-A1 | CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2022-08-25 | — | — | US | claimed |
| US-12617767-B2 | Crystalline forms of somatostatin modulators | Crinetics Pharmaceuticals, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240376067-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2024-11-14 | — | — | US | disclosed |
| EP-4092018-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220267295-A1 | CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2022-08-25 | — | — | US | disclosed |
| EP-3740475-B1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | CRINETICS PHARMACEUTICALS INC (US) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267295-A1 | CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR3 | CKS1B 2273/4885SKP1 2199/4885SKP2 3528/4885 |
| US-12617767-B2 | Crystalline forms of somatostatin modulators | IAPP, SSTR2, SSTR3 | CKS1B 328/4885SKP1 103/4885SKP2 1844/4885 |
| US-20240376067-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | CKS1B 2307/4885SKP1 2781/4885SKP2 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.